Silymarin Protects Against Liver Damage, treatment options for chronic hepatitis

Silymarin Protects Against Liver Damage, treatment options for chronic hepatitis

new treatment options for chronic hepatitis

Darrell Miller

05/30/05

Date: May 30, 2005 10:11 AM
Author: Darrell Miller (dm@vitanetonline.com)
Subject: new treatment options for chronic hepatitis

Can science meet the challenges of the HCV pandemic: new treatment options for chronic hepatitis C. Roehr B Journal of the International Association of Physicians in AIDS Care (1998 Jul), 4(7), 24-9. Journal code: 9508185. ISSN:1081-454X. United States. (NEWSPAPER ARTICLE) written in English. PubMed ID 11365638 AN 2001282246 MEDLINE

Abstract

New treatment options for chronic hepatitis C (HCV) infection are examined. Studies show the efficacy of interferon alfa-2b in normalization of serum alanine aminotransferase and histological improvement in necroinflammatory liver disease. However, 70 to 80 percent experiencing normalization usually relapse within 1 year after treatment. Ten to 20 percent will have a sustained response lasting at least 3 years. Ideas for improving treatment response include longer initial treatment regimens, increasing dosages of interferon alpha, or adding another agent to interferon alpha. Based on encouraging study results, the interferon/ribavirin combination has been approved by the Food and Drug Administration (FDA) in HCV patients relapsing following interferon alpha monotherapy. So far the FDA has approved interferon alfa-2b, interferon alfa-2a, alfacon-1, and interferon alfa-2b/ribavirin as treatments for HCV; ribavirin alone is not effective against HCV infection. Other drugs are being tested with interferon alpha but have not generated enough substantive data. Thymosin, an immune modulator that enhances the body's production of interferon and interleukin rather than attacking HCV directly, is also being investigated. Oral dosing of interferon is in clinical trials for hepatitis B, and the results may be applicable to HCV. Alternative therapies are gaining wider interest such as using milk thistle for liver regeneration or using licorice root for quelling liver inflammation. As for transmission risk, there is little evidence supporting sexual activity as a major risk factor, however, some risk is reported with anal intercourse, sex during the menstrual cycles, and years of cohabitation with an infected partner.

Milk thistle had successful results in hepatitis B amd possibly Hepatitis C.